The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
GENETICS OF NATURAL POPULATIONS. XIII. RECOMBINATION AND VARIABILITY IN POPULATIONS OF DROSOPHILA PSEUDOOBSCURA
Open accessAbstract
Th Dobzhansky; GENETICS OF NATURAL POPULATIONS. XIII. RECOMBINATION AND VARIABILITY IN POPULATIONS OF DROSOPHILA PSEUDOOBSCURA, Genetics, Volume 31, Issue 3, 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GENETIC VARIABILITY, TWIN HYBRIDS AND CONSTANT HYBRIDS, IN A CASE OF BALANCED LETHAL FACTORS
Muller, H. J. (1918) · Genetics · doi:10.1093/genetics/3.5.422 · Cited by 336
Wright, S., & Dobzhansky, T. (1946) · Genetics · doi:10.1093/genetics/31.2.125 · Cited by 325
Self-citationVariation and selection of polygenic characters
Mather, K. (1941) · Journal of Genetics · doi:10.1007/bf02983019 · Cited by 212
CORRELATED RESPONSE TO THE SELECTION OF POLYGENIC CHARACTERS
Wigan, L. G., & Mather, K. (1941) · Annals of Eugenics · doi:10.1111/j.1469-1809.1941.tb02299.x · Cited by 29
ISO-ALLELES AT THE BOBBED LOCUS IN DROSOPHILA HYDEI POPULATIONS
Spencer, W. P. (1944) · Genetics · doi:10.1093/genetics/29.6.520 · Cited by 17
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Design and synthesis of a minimal bacterial genome
Hutchison, C. A., Chuang, R.-Y., Noskov, V. N., Assad-Garcia, N., Deerinck, T. J., Ellisman, M. H., Gill, J., Kannan, K., Karas, B. J., Ma, L., et al. (2016) · Science · doi:10.1126/science.aad6253 · Cited by 1,500
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Protein-protein interactions: methods for detection and analysis.
Phizicky, E. M., & Fields, S. (1995) · Microbiological reviews · doi:10.1128/mmbr.59.1.94-123.1995 · Cited by 966
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Drug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
The population genetics of speciation: the evolution of hybrid incompatibilities
Orr, H. A. (1995) · Genetics · doi:10.1093/genetics/139.4.1805 · Cited by 785
Genetic revolutions, founder effects, and speciation
Barton, N. H., & Charlesworth, B. (1984) · Annual Review of Ecology and Systematics · doi:10.1146/annurev.es.15.110184.001025 · Cited by 681
Exploring genetic interactions and networks with yeast
Boone, C., Bussey, H., & Andrews, B. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2085 · Cited by 661
Synthetic lethality and cancer
O'Neil, N. J., Bailey, M. L., & Hieter, P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.47 · Cited by 658
A NEO‐DARWINIAN COMMENTARY ON MACROEVOLUTION
Charlesworth, B., Lande, R., & Slatkin, M. (1982) · Evolution · doi:10.1111/j.1558-5646.1982.tb05068.x · Cited by 605
Yeast: An Experimental Organism for 21st Century Biology
Botstein, D., & Fink, G. R. (2011) · Genetics · doi:10.1534/genetics.111.130765 · Cited by 604
Adams, A. E., Johnson, D. I., Longnecker, R. M., Sloat, B. F., & Pringle, J. R. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.1.131 · Cited by 603
Genetics and the Fitness of Hybrids
Burke, J. M., & Arnold, M. L. (2001) · Annual Review of Genetics · doi:10.1146/annurev.genet.35.102401.085719 · Cited by 558
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 449
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 426
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Orr, H. A. (1997) · Annual Review of Ecology and Systematics · doi:10.1146/annurev.ecolsys.28.1.195 · Cited by 333
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Nijman, S. M. B. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.024 · Cited by 319
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Systematic Mapping of Genetic Interaction Networks
Dixon, S. J., Costanzo, M., Baryshnikova, A., Andrews, B., & Boone, C. (2009) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.073003.114751 · Cited by 295
THE EFFECT OF AN EXPERIMENTAL BOTTLENECK UPON QUANTITATIVE GENETIC VARIATION IN THE HOUSEFLY
Bryant, E. H., McCommas, S. A., & Combs, L. M. (1986) · Genetics · doi:10.1093/genetics/114.4.1191 · Cited by 289
The Language of Gene Interaction
Phillips, P. C. (1998) · Genetics · doi:10.1093/genetics/149.3.1167 · Cited by 273
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Coleman, R. L., Sill, M. W., Bell-McGuinn, K., Aghajanian, C., Gray, H. J., Tewari, K. S., Rubin, S. C., Rutherford, T. J., Chan, J. K., Chen, A., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.042 · Cited by 265
Global Genetic Networks and the Genotype-to-Phenotype Relationship
Costanzo, M., Kuzmin, E., van Leeuwen, J., Mair, B., Moffat, J., Boone, C., & Andrews, B. (2019) · Cell · doi:10.1016/j.cell.2019.01.033 · Cited by 241
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
Genetic interactions reveal the evolutionary trajectories of duplicate genes
VanderSluis, B., Bellay, J., Musso, G., Costanzo, M., Papp, B., Vizeacoumar, F. J., Baryshnikova, A., Andrews, B., Boone, C., & Myers, C. L. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.82 · Cited by 110
Synthetic Lethality in Ovarian Cancer
Chandrasekaran, A., & Elias, K. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0500 · Cited by 41
C16orf72/HAPSTR1 is a molecular rheostat in an integrated network of stress response pathways
Amici, D. R., Ansel, D. J., Metz, K. A., Smith, R. S., Phoumyvong, C. M., Gayatri, S., Chamera, T., Edwards, S. L., O’Hara, B. P., Srivastava, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111262119 · Cited by 29
Metadata
- Authors
- Dobzhansky, T.
- Venue
- Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 1946-05-01
- Volume
- 31
- Issue
- 3
- Pages
- 269-290
- ISSN
- 0016-6731 (ISSN-L)
- 1943-2631
- OpenAlex
- W2279299471
- Cited by
- 427
- References
- 5
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.